{
  "parties": [
    "NLS-1 Pharma AG Alter Postplatz 2 6370 Stans Switzerland \"Licensor\" / \"NLS\"",
    "Eurofarma Laborat√≥rios S"
  ],
  "effective_date": null,
  "governing_law": null,
  "payment_terms": {
    "text": "Payment Terms 7 4. Business Plan 7 5. Development Work 8 6. Further Development Work 8 7. Brand Name and Trademarks 9 8. Labelling and Packaging 9 9. Regulatory Obligations and Procedures 10 9.1. Regulatory Obligations and Procedures in General 10 9.2. Notifications 10 9.3. Regulatory Obligations of Licensee 10 9.4. Regulatory Obligations of Licensor 10 9.5. Pharmacovigilance 11 10. Cooperation and Joint Project Steering Committee 11 10.1. Cooperation 11 10.2. Transfer of Know-how 11 10.3. Joint Steering Committee 12 11. Commercialization 12 12. Supply 13 13. Property rights to Intellectual Pr",
    "start": 734,
    "end": 1334,
    "confidence": 0.72,
    "source": "regex"
  },
  "termination_clause": {
    "text": "Termination 18 19.1. Term 18 19.2. Termination for Change of Control 18 19.3. Termination for Bankruptcy, Liquidation and similar proceedings 18 19.4. Early Termination for Material Breach 18 19.5. Early Termination by the Licensor 19 19.6. Early Termination by the Licensee 19 19.7. Consequences of Expiration or Termination 20 20. General Provisions 20 20.1. Amendments 20 20.2. Notices 20 20.3. Severability / Good Faith 20 20.4. No Waiver 21 20.5. No Assignment 21 20.6. Appendices 21 20.7. Public Announcements 21 21. Governing Law and Jurisdiction 21 Table of Appendices 23 Appendix A - [Template for Licensee Reports] 24 Appendix B - Preliminary Business Plan 25 Appendix C*- Purpose of the JSC pre and post MA * No such appendix completed by the parties.\n\nii\n\nSource: NLS PHARMACEUTICS LTD., F-1, 2/28/2",
    "start": 2042,
    "end": 2853,
    "confidence": 0.72,
    "source": "regex"
  },
  "_doc_id": "NlsPharmaceuticsLtd_20200228_F-1_EX-10.14_12029046_EX-10.14_Development Agreement.txt",
  "_char_count": 67932,
  "_provenance": {}
}